Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
about
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyStriving for optimal bronchodilation: focus on olodaterolPrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Copd.Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies.Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study.Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasoneIndacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.Olodaterol attenuates citric acid-induced cough in naïve and ovalbumin-sensitized and challenged guinea pigsInhaled β-agonist does not modify sympathetic activity in patients with COPD.Indacaterol (arcapta neohaler) for chronic obstructive pulmonary diseaseIndacaterol in chronic obstructive pulmonary disease: an update for clinicians.Novel long-acting bronchodilators for COPD and asthmaLong-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.Developments in drugs for the treatment of chronic obstructive pulmonary disease.Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist.Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.An update on the use of indacaterol in patients with COPD.Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD.Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.Indacaterol: a novel long-acting β(2) -agonist.Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma.Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist.Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonistsSystematic review comparing LABA, olodaterol, and indacaterol: limitations.Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
P2860
Q21257191-5A1B10B0-E234-4E9D-B11E-17C7DECE7F2CQ26752887-64FF52E0-CC17-4F71-A95B-454FE1820C30Q27348844-84D3C7AE-48CF-4692-83FC-D1B884298BACQ31016356-F35665E7-5E16-4E98-9B92-3F46013D5075Q33780109-1A702345-6BFD-4773-AC29-F375C2F585DFQ33912856-333441F3-B6A9-45F5-B470-9FB181F29FE8Q34011640-3C5647E0-66FE-4933-BB82-C3C3F935805EQ34128947-1FA44F89-88E5-4166-8466-633E07C1A398Q34243574-691C26E6-A080-4142-B436-C4DF44434E03Q34544020-C50D4453-BEEF-435A-A963-9E68B1B98425Q35190258-3E736BBC-E378-4A85-9AE1-A55519ACE38CQ35618080-95869300-FFAD-43E1-A85D-74F8100DE29FQ35958673-80FF5C00-7FAA-4E70-A94A-BB4E95CE2A42Q36443777-CE76570C-E6A6-4E40-A68F-FE25B4275CF0Q37208308-232444DB-33F3-4599-BF7C-277E15F7CDB7Q37310689-EED68514-99E2-4889-9523-8DAEED6EF97FQ37487619-1CFE706D-ACC6-42DB-9C62-BBB9B0F474E2Q37754541-1B47CCBF-3083-4A8F-A17A-322BE6224BBEQ37773997-03EE80A9-3F52-4E99-A3E2-7E6BC53044FCQ37778736-D577B7BE-0EA7-4058-A355-1BD2CDAB2486Q37804908-0075FCE5-D8B8-4217-94C8-90D3E488DC7FQ37808058-B2AC6BBE-F1E8-4AF6-889F-D9663AD25559Q37846698-7668D766-894E-4021-AD9C-3A380FA41386Q37911291-F838F6D2-D75C-4624-A7EB-080FF5178086Q37999465-6338E54D-AB65-4A73-BBB9-D31DB7B001CEQ38002357-36D97B1A-6685-4702-A612-6A900C0AB84BQ38248438-F0840E8F-8336-4401-956A-D22E2B19448FQ38947467-C0BE0D21-E3DC-4A1B-A3B4-05E448B94166Q39855476-7714D54A-3B06-41D1-AAB3-F07695122EA0Q42170464-16FE3C2F-89DA-4D07-9DAD-032D29EE5425Q42283741-F22624A7-B49E-402E-9A78-0D117DB9FF4CQ42634011-B516C928-F1A2-464B-BECA-BA0B7294B42CQ42776525-F1283E8A-4F31-4A13-A31F-0EF84C506065
P2860
Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Safety, tolerability and effic ...... ebo controlled clinical trial.
@en
Safety, tolerability and effic ...... ebo controlled clinical trial.
@nl
type
label
Safety, tolerability and effic ...... ebo controlled clinical trial.
@en
Safety, tolerability and effic ...... ebo controlled clinical trial.
@nl
prefLabel
Safety, tolerability and effic ...... ebo controlled clinical trial.
@en
Safety, tolerability and effic ...... ebo controlled clinical trial.
@nl
P2093
P1476
Safety, tolerability and effic ...... ebo controlled clinical trial.
@en
P2093
A J M Schreurs
Damon Jack
Jean-Benoit Martinot
Jutta Beier
Mark Higgins
Pascal Chanez
Ruzena Tkácová
Weibin Bao
P304
P356
10.1016/J.PUPT.2006.09.001
P577
2006-09-30T00:00:00Z